JVS-100 干细胞疗法: Stromal cell-Derived Factor 1 (SDF-1)

Juventas 获2200万美元投资用于干细胞药物研发  发布时间：2012-7-17 来源：药品资讯网信息中心在试图融资一年多后，Juventas制药最终募集到了2220万美金的投资。这些资金将被用于一个还在研究中的治疗方法，使用干细胞药物JVS-100进行心脏衰竭及严重肢端缺血的再生治疗。参与投资的公司包括Triathlon Medical Venture Partners、New Science Ventures、Fletcher Spaght Ventures、Reservoir Venture Partners以及Early Stage Partners。它们的投资被用于支持关于编码细胞基质衍生因子-1的成体干细胞疗法的研究。2011年的春天，Juventas制药曾表示这项研究的进行大约需要2500万美元。Juventas制药的CEO Rahul Aras称，第二轮的投资将极大的推进公司的研究。更多的投资者参与到了对这一项目的投资中，也证明了Juventas公司独特疗法的潜力，以及社会对于再生医学的关注。目前Juventas制药正在积极筹备研究的启动。新生的药物公司SironRX制药目前正致力于关于JVS-100在皮肤和骨治疗应用的研究。2011年，SironRX分别从North Coast Angel基金会和Ohio Third Frontier计划募集到了共计440万美元用于推进这项研究。

Juventas begins enrollment in JVS-100 Phase IIa study for Rutherford Class 4 or 5 CLI  Published on May 16, 2012 at 12:37 AM  Juventas Therapeutics, a privately-held, clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, is pleased to report that it is actively enrolling patients in a placebo-controlled, randomized double-blinded Phase IIa study evaluating the safety and efficacy for JVS-100 in patients with Rutherford Class 4 or 5 critical limb ischemia (CLI).  JVS-100, the Company's lead product, encodes Stromal cell-Derived Factor 1 (SDF-1) which has been shown to repair damaged tissue through recruitment of circulating stem cells to the site of injury, prevention of ongoing cell death and restoration of blood flow.  Patients are enrolling at Northwestern Memorial Hospital, Cardiology PC, Minneapolis Heart Institute Foundation, and Summa Health Systems.  In addition, the Company is enrolling patients at three leading cardiovascular institutions in India; Medanta the Medicity, Sir Ganga Ram, and Fortis Escorts Heart Institute."We are excited to be participating in the STOP-CLI trial," says Melina Kibbe, M.D., principal investigator for the study and the Edward G. Elcock Professor of Surgical Research at the Northwestern University School of Medicine. "CLI is a devastating disease for which there are no good therapeutic options.  JVS-100 is a regenerative therapy with the potential to improve clinical outcomes for these patients." There are an estimated 3 million Americans suffering with CLI. The prognosis for these patients is 25% mortality and 35% major amputation rates within a year of diagnosis. "Juventas is committed to developing novel regenerative therapies for life-threatening cardiovascular diseases," states Rahul Aras, Ph.D., President & CEO for Juventas Therapeutics.  "The initiation of this trial, with top-tier clinical centers, represents an exciting milestone for the Company."

SOURCE Juventas Therapeutics